ViGeneron GmbH
π©πͺGermany
- Country
- π©πͺGermany
- Ownership
- Holding
- Established
- 2017-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.vigeneron.com
Clinical Trials
3
Active:1
Completed:0
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)β’ Click on a phase to view related trials
Phase 1
3 (100.0%)Safety and Preliminary Efficacy of VG801 in Patients With ABCA4 Mutation-associated Retinal Dystrophy (Stargardt Disease)
Phase 1
Recruiting
- Conditions
- Retinal Dystrophy Due to Biallelic ABCA4 MutationsStargardt Disease 1
- Interventions
- First Posted Date
- 2025-06-03
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- ViGeneron GmbH
- Target Recruit Count
- 15
- Registration Number
- NCT07002398
- Locations
- π¨π³
Shanghai General Hospital, Shanghai, Shanghai, China
Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene
- First Posted Date
- 2024-03-04
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- ViGeneron GmbH
- Target Recruit Count
- 6
- Registration Number
- NCT06291935
- Locations
- π©πͺ
Center for Ophthalmology, University of Tuebingen, Tuebingen, Germany
News
No news found